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 Abstract 
 Background: Alzheimer’s disease (AD) and Parkinson’s disease (PD) are associated with severe 
cognitive decline, but it is still unclear to what extent they become functionally more similar 
over time.  Methods: We compared amnestic mild cognitively impaired (aMCI; n = 29) patients 
to mild cognitively impaired (MCI) PD patients (n = 25), and patients with AD (n = 34) to pa-
tients with PD dementia (PDD; n = 15) with respect to cognitive functioning and mood.  Re-
sults: aMCI patients were impaired in episodic memory, while MCI PD patients showed defi-
cits in visuoconstruction and attention. AD and PDD patients showed comparable deficits on 
tests for language, attention and visuoconstruction. However, unlike PDD patients but similar 
to aMCI patients, AD patients showed a characteristic memory impairment, especially com-
mission errors on recognition tasks, whereas PDD patients scored higher on the depressive 
mood questionnaire.  Conclusions: In advanced stages of both diseases, the pattern of func-
tional deficits associated with parietal and temporal lobe functions (attention, visuoconstruc-
tion and language) is similar. However, specific differences, already present in the early stage 
(recognition errors in AD, associated with mediobasal temporal lobe functioning, and de-
pressed mood in PDD, associated with non-motor basal ganglia loops), are also observed in 
the late stage.  Copyright © 2013 S. Karger AG, Basel 
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 Introduction 
 Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most frequent neurode-
generative disorders. AD is characterized by a progressive cognitive decline. However, also 
the majority of PD patients develops dementia in the course of the disease, and a considerable 
number of patients already shows cognitive deficits in the early stage, which are severe 
enough to be diagnosed as dementia  [1–5] .
 Several neuropsychological studies have investigated whether the pattern of cognitive 
deficits in AD can be distinguished from that in PD  [6–10] . There is now a fair consensus that 
AD is characterized by a severe decline in episodic memory, whereas PD is typically asso-
ciated with executive and visuoconstructive deficits in combination with psychomotor 
slowing  [11, 12] . Nonetheless, these conclusions are mainly based on an indirect comparison 
of patients suffering from each of these disorders with healthy control groups, and the num-
ber of studies directly comparing these two patient groups is rather small  [13–16] .
 From a neuropathological point of view and against the background of disease-specific 
pathogenetic processes, it can be argued that AD and PD patients should show different 
patterns of cognitive deficits. For instance, according to the Braak stages in AD, the devel-
opment of neurofibrillary tangles starts in the entorhinal cortex, extends into the hippo-
campus and then spreads to secondary association cortices  [17] . In PD, neurodegeneration 
starts in the brain stem, extends into the midbrain, affecting the substantia nigra, and subse-
quently into cortical areas  [17] . These differences in neuropathological changes should lead 
to an increasing difference in cognitive impairments during the progression of the two 
diseases. However, more recent neuropathological studies have challenged this view  [18, 19] . 
In fact, several animal studies have recently shown that Lewy-related pathology may stim-
ulate the development of beta-amyloid plaques and vice versa  [17, 20] . Furthermore, post-
mortem neuropathological studies have shown that many PD patients fulfill the criteria of AD 
on neuropathological grounds  [21] .
 These findings cast some doubt on the notion that the two diseases are characterized by 
different patterns of cognitive deficits. The strongest evidence for an interaction between 
accumulation of alpha-synuclein in Lewy bodies and beta-amyloid in plaques stems from 
animal research  [17, 20] because in humans this interaction cannot be studied, at least not 
until valid biomarkers for the progressive development of Lewy bodies and beta-amyloid 
plaques are available. The question whether these neuropathological processes interact also 
in patients with AD or PD can be addressed, to some extent, by looking at behavioral data. 
More specifically, we can study whether the pattern of deficits becomes increasingly similar 
in the course of the diseases. Yet, the number of studies directly comparing patients with AD 
and PD in the course of their illness is quite small and in some of these studies the Mini-
Mental State Examination (MMSE) is used, which, however, is not very sensitive  [9, 14, 16, 
21] . We have shown that on a recognition task, AD patients typically made commission 
errors (false positives). This specific deficit correlated with biomarkers like beta-amyloid 
and total tau  [22, 23] , and this task seems to be sensitive to early cognitive problems in AD. 
In the current study, we extend our previous research by comparing patients with AD and 
PD, either in an early state of mild cognitive impairment (MCI) or in a state of dementia, 
specifically addressing the following questions: (1) Is the pattern of cognitive deficits in AD 
and PD similar in an early stage (i.e. of MCI) and in a severe state of cognitive decline? (2) 
Are commission errors characteristic for AD patients, both in an early and late phase of the 
disease?
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 Methods 
 Patients 
 Twenty-nine patients with amnestic MCI (aMCI), 25 patients with PD and MCI but no 
dementia, 34 patients with probable AD and 15 patients with PD dementia (PDD) were 
included ( tables 1 ,  2 ). Patients were invited to participate in this study after their admission 
to the neurological departments of the two hospitals involved. All diagnoses were based on 
the guidelines of the German Neurological Society, which are updated every 3–5 years to 
follow the international consensus processes (http://www.dgn.org/images/stories/dgn/
pdf/s3_leitlinie_demenzen.pdf). The diagnosis of AD was based on clinical examination, 
neuropsychological assessment and on a decreased beta-amyloid (<375 pg/ml) or increased 
total tau level (>448 pg/ml)  [24] . Disease severity of the PD patients was assessed using the 
Hoehn and Yahr scale  [25] . For both groups (AD and PDD), a sum score below 25 in the MMSE 
was defined as cutoff score for diagnosing a dementia syndrome. aMCI patients scored 1.5 SD 
or more below the standard population mean on the word list learning task (see below) and 
reported a decrease in memory function. MCI PD patients scored 1.5 SD or more below the 
mean on at least one of the neuropsychological tests applied. Patients with any other neuro-
logical or psychiatric disease unrelated to MCI, AD and PD were excluded. Exclusion was 
Table 1.  Patients with AD and PDD
AD (females: 23, males: 11) PDD  (females: 10, males: 5)
mean median SD me an median SD
Age, years 71.2 72.0 7.6 73.3 74.0 7.4
Education, years 12.8 12.0 3.5 11.3 12.0 2.6
MMSE 17.0 18.0 5.6 18.9 22.0 6.0
Tau protein, pg/ml 767 531 578 – – –
Beta-amyloid, pg/ml 357 357 121 – – –
Hoehn and Yahr stage – – – 3.3 3 0.6
Beck Depression Inventory* 8.9 5.0 9.9 14.2 15.5 6.1
Rey Verbal Comprehension 4.1 5.0 1.6 3.9 4.0 1.0
Mehrfachwahl-Wortschatz-Intelligenztest 24.8 25.5 7.9 24.4 24.0 4.5
Boston Naming Test1 12.1 11.0 3.7 12.5 13.0 2.2
Semantic fluency1 10.6 10.5 5.9 10.9 9.0 6.1
LPS subtest 6 (phonological fluency) 16.5 14.0 9.0 16.6 15.5 4.8
ZVT, s 111.2 77.3 95.8 82.0 53.5 62.0
Digit Span forward 5.8 6.0 1.9 6.5 6.5 2.6
Digit Span backward 3.6 4.0 1.7 3.3 3.0 1.9
Copying1 8.0 8.0 2.3 7.8 8.0 2.1
Word list learning1, * 8.1 8.0 3.9 11.1 12.0 5.8
Word list delayed recall1 1.4 1.0 1.7 2.1 2.0 2.1
Word list intrusions1 1.9 1.0 2.6 1.1 1.0 1.8
Word list savings1 35.2 33.0 36.8 40.1 40.0 35.7
Visuoconstructive delayed recall1 1.9 1.0 2.4 2.7 3.0 2.9
Visuoconstructive savings1 22.4 13.0 26.4 31.5 36.0 32.6
Word list discriminability1 73.8 75.0 14.1 83.7 85.0 13.2
Word list recognition: correct hits1 3.1 2.0 2.8 2.5 3.0 1.5
Word list recognition: correct rejections1, * 2.1 1.0 2.4 0.9 0.0 1.8
Visual recognition task: omissions 4.4 3.0 3.6 5.3 5.0 3.6
Visual recognition task: commissions* 5.3 4.5 4.1 2.5 1.0 3.1
 1 CERAD-NP battery. * p < 0.05.
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based on the report of the patients, serological screening and on inspection of CCT or MRI 
scans. Twenty healthy individuals were recruited on an informal basis in our clinic and 
through an announcement at a location where elderly people meet. The project was approved 
by the Ethics Committee of the University of Oldenburg, Germany, and all patients gave their 
informed consent.
 Neuropsychological Investigation 
 All participants (patients and healthy controls) underwent a neuropsychological exami-
nation, including the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) test 
 [26] series, composed of the MMSE, a 15-item short version of the Boston Naming Test, 
semantic word fluency for the animal category (1 min), word list learning (reading aloud of 
10 words with the instruction to memorize the items, three trials), delayed recall of the word 
list (after the copying task), recognition (10 targets from the word list and 10 distractor 
words, directly after delayed recall), figure copying and delayed figure recall. We also used 
the letter fluency task from the  Leistungsprüfsystem (LPS) 50+ Test  [27] , the German version 
of the FAS test. Further, we used the  Zahlenverbindungstest  (ZVT)  [28] , which is similar to the 
Trail Making Test, Version A. We used the Digit Span forward and backward from the German 
version of the Wechsler Memory Scale (revised)  [29] to investigate verbal working memory 
Table 2. Patients with aMCI and MCI PD
Healthy controls aMCI MCI PD
(females: 10, males: 10) (females: 14, males: 11) (females: 16, males: 13)
mean median SD mean median SD mean median SD
Age, years 68.8 74.0 14.9 69.7 71.0 9.1 71.1 73.0 7.9
Education, years 13.3 12.0 2.5 12.9 12.5 2.8 12.4 12.0 2.3
MMSE 28.8 29.0 0.5 26.2 26.0 2.5 27.8 28.0 1.4
Tau protein, pg/ml – – – 459 355 356 – – –
Beta-amyloid, pg/ml – – – 658.2 637 302.7 – – –
Hoehn and Yahr Scale – – – – – – 3.4 3.5 0.5
Beck Depression Inventory 5.4 5.3 1.3 10.1 9.0 6.8 9.6 8.0 6.8
Rey Verbal Comprehension 1.00 1.00 2.65 3.00 1.50 2.52 2.00 1.94
Mehrfachwahl-Wortschatz-Intelligenztest 31.8 31.5 2.1 28.0 30.0 4.9 27.6 27.0 5.2
Boston Naming Test1 15.0 15.0 0.0 13.9 14.0 3.3 14.0 15.0 1.4
Semantic fluency1 18.8 19.5 6.7 13.2 13.0 3.2 15.0 16.0 5.7
LPS subtest 6 (phonological fluency) 27.5 26.5 6.2 22.0 22.0 8.9 21.7 21.0 8.7
ZVT, s* 34.3 36.0 10.8 45.9 34.0 25.7 83.9 70.0 53.5
Digit Span forward* 9.3 9.5 1.0 6.4 6.0 1.9 8.1 8.0 2.3
Digit Span backward 8.0 8.0 1.6 5.6 5.0 4.6 5.4 5.0 1.8
Copying1, * 10.3 11.0 1.5 9.4 10.0 1.2 9.0 9.0 2.0
Word list learning1 22.3 21.0 4.0 13.6 15.0 3.8 16.6 17.0 5.0
Word list delayed recall1, * 6.3 5.5 1.9 3.5 3.0 2.0 5.5 5.0 1.4
Word list intrusions1 0.8 1.0 0.5 0.9 0.0 1.2 0.9 1.0 1.7
Word list savings1, * 73.8 74.5 16.8 63.6 67.0 32.9 82.8 84.0 16.2
Visuoconstructive delayed recall1 9.5 9.5 1.7 5.1 5.0 2.7 6.8 7.0 3.2
Visuoconstructive savings1 93.3 100.0 13.5 53.6 56.0 27.4 73.6 75.0 29.5
Word list discriminability1 97.5 100.0 5.0 88.6 90.0 9.6 94.8 95.0 7.0
Word list recognition: correct hits1 0.5 0.0 1.0 1.4 1.0 1.4 0.9 0.0 1.4
Word list recognition: correct rejections1 0.5 0.0 1.0 0.8 0.0 1.0 0.2 0.0 0.5
Visual recognition task: omissions 0.5 0.5 0.6 2.0 1.0 1.7 1.5 1.0 1.7
Visual recognition task: commissions* 0.5 0.5 0.6 2.8 1.0 3.2 0.8 0.0 1.0
1 CERAD-NP battery. * p < 0.05 comparing aMCI with MCI PD patients.
D
ow
nl
oa
de
d 
by
: 
R
ad
bo
ud
 U
ni
ve
rs
ite
it 
Ni
jm
eg
en
    
    
    
    
    
    
  
14
9.
12
6.
75
.1
 - 
10
/1
2/
20
15
 1
2:
21
:0
5 
PM
106Dement Geriatr Cogn Disord Extra 2013;3:102–112
 DOI: 10.1159/000348350 
E X T R A
 Hildebrandt et al.: Cognitive Profiles of Patients with Mild Cognitive Impairment or 
Dementia in Alzheimer’s or Parkinson’s Disease 
www.karger.com/dee
© 2013 S. Karger AG, Basel
performance. The  Mehrfachwahl-Wortschatz-Intelligenztest (multiple choice vocabulary 
intelligence test  [30] ) was taken as a measure for the ability to discriminate between words 
and pseudowords. A German version of the Rey Verbal Comprehension task was used to test 
sentence comprehension and for constructing geometrical figures. The Beck Depression 
Inventory  [31] was used to investigate mood. Neuropsychological examination was performed 
by an experienced and certified neuropsychologist.
 Investigation of Validity in Recognition 
 In previous studies, we have successfully used a specially designed picture recognition 
task  [22, 32] . Participants were asked to name 16 pictures and were not informed that they 
would be asked to recognize these later. After 15 min, 24 recognition trials were given, each 
trial now encompassing 3 different pictures stemming from the same category, e.g. 3 insects, 
to increase discrimination difficulty. In 8 of the recognition trials, no picture was present that 
had been shown before, on 16 trials one of the three pictures had been shown before. The 
participants had to decide whether one of the three pictures had been shown before and, if 
so, which one. Misses were counted as omissions, false positive as commissions.
 Neurological Investigation 
 All patients received a standard diagnostic examination, including medical history, 
physical and neurological examination, laboratory testing, brain imaging and electroenceph-
alography. Blood sample analysis included determination of blood count, erythrocyte sedi-
mentation rate, electrolytes, creatine, urea, transaminases, blood glucose, TSH and C-reactive 
protein. A lumbar puncture was performed by a trained neurologist in each aMCI and prob-
able AD patient. 
 Statistical Analysis 
 For non-parametric testing, the Mann-Whitney U test was used to compare the patient 
groups. Since we anticipated that the healthy controls would perform better than any of the 
patient groups, analyses comparing healthy controls with patients were not performed.
 In a first analysis, aMCI patients were compared to MCI PD patients irrespective of the 
MMSE score. In a second step, we matched the two groups using the MMSE score by 
restricting the range of MMSE scores, increasing the lowest MMSE value from 25 to 26 and 
decreasing the highest MMSE value from 30 to 29. This resulted in the inclusion of 19 aMCI 
and 13 MCI PD patients and in a non-significant difference on the MMSE. Subsequently, AD 
patients were compared to PDD patients. Finally, aMCI patients were compared to AD 
patients and MCI PD to PDD patients to look for disease-specific differences in the pattern 
of cognitive deficits.
 Results 
 Age, gender and average scores on each of the tasks for the different groups of partici-
pants are summarized in  tables 1 and  2 . Notably, the two groups with MCI (aMCI vs. PD) and 
with dementia (AD vs. PDD) did not differ in age, education and MMSE score.
 Differences between Diseases 
 After matching for disease severity by adapting criteria for the MMSE scores (see above), 
aMCI and MCI PD patients differed significantly on attention tests (ZVT: p = 0.021, Digit Span 
forward: p = 0.028), episodic memory (word list delayed recall: p = 0.02, word list savings: p =
0.018, word list recognition commission errors: p = 0.014), and visuoconstruction (figure 
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copying: p = 0.041). MCI PD patients were slower than aMCI patients and solved less visuo-
constructional tasks, but reproduced more digits and words. The same analyses for the entire 
group of patients gave the same pattern of results.
 AD and PDD patients only differed significantly in commission errors on the experimental 
visual recognition task (p = 0.027), in commission errors on the word list recognition task
(p = 0.049) and in depressive mood (p = 0.024), but not in visuoconstruction and attention. 
AD patients made more errors but showed less depressive mood than PDD patients.
 Taken together, the results show that PD patients, both in the early and late phase, 
differed from patients with aMCI and probable AD in commission errors, but not in omissions.
 Differences in Severity 
 For both disorders, the groups with dementia showed a more severe and broader 
impairment with respect to language and memory functions than patients in the early phase 
suffering from MCI (see columns 1 and 3 of  table 2 ). AD patients differed significantly from 
aMCI patients in attention (ZVT, p = 0.001), but PD patients did not. The same applies for 
visuoconstruction (p = 0.015). PDD patients differed from MCI PD patients in depressive 
mood (p = 0.018), but aMCI and AD patients did not differ with respect to depression.
 Interestingly, both groups with dementia performed worse compared to their MCI groups 
in recognition performance (discriminability index of the CERAD word list learning: AD 
patients: p < 0.001; PD patients: p = 0.009). Apparently, they do so for different reasons: 
whereas AD patients, compared to aMCI patients, showed a significant increase in omissions 
(visual recognition task: p = 0.002; word list recognition task: p = 0.015) and in commissions 
(visual recognition task: p = 0.015; word list recognition task: p = 0.019) on both recognition 
 Fig. 1. Only aMCI and AD patients performed more commissions than omissions in the visual recognition 
task. Moreover, aMCI patients differed from PD MCI patients in CERAD word list commissions, and patients 
with AD differed from patients with PDD. 
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tasks, patients with PDD showed a significant increase only for omissions on both recognition 
tasks (visual recognition task: p = 0.001; word list recognition task: p = 0.003) ( fig. 1 ).
 A comprehensive overview of significant differences between the four groups is presented 
in  table 3 .
 Discussion 
 As observed in earlier investigations  [15, 33] , MCI PD patients suffered from attentional 
and visuoconstructive deficits, whereas episodic memory impairments were detected in 
patients with aMCI. However, in an advanced stage of the two diseases, the deficits in attentional 
or language functions and visuoconstruction were similar. In contrast, depressive mood was
a distinctive feature in PDD, but was not increased in AD. AD and PDD patients differed in learn-
ing (not in delayed recall), and AD patients made more commission errors than PDD patients. 
 In advanced AD and PDD, similar patterns of cognitive deficits were observed, particu-
larly involving language functions, attention and visuoconstructive functions. These cognitive 
domains rely largely on temporal and parietal areas: visual attention and visuoconstructive 
performance are related to the integrity of the right parietal lobe, whereas verbal working 
memory (Digit Span, which is often classified as a test of attention) and verbal fluency are 
associated with the left parietal and temporal areas  [34] . It is well known that, in neuropatho-
logical terms, AD starts in the mediotemporal lobe, but during the Braak stage V it spreads to 
the temporoparietal areas. Enlarged sulci  [35, 36] and hypoperfusion of these areas  [37] are 
hallmarks of AD progression. For PD, impairments in visuoconstruction and attention belong 
to the defining and early features of PDD and seem to be due to cognitive slowing (visual 
attention and verbal working memory) and impaired executive functions  [10, 12, 33, 38] . 
According to our findings, the deficits worsen somewhat over the course of the disease, as 
documented by significant decrements on tests for these functions between MCI PD and PDD 
patients, but this progress seems to be smaller than that in AD. Consequently, the patterns of 
deficit seem to lose their specificity during the disease course.
Table 3. Significant differences between groups according to disease etiology and disease stage
Significant differences in
aMCI ZVT, DS forward, word list delayed recall, 
word list savings, word list recognition 
commission errors, copying 
MCI PD
ZVT, DS backward, naming, FAS, semantic 
fluency, verbal comprehension, omissions 
and commissions in visual recognition, 
word list learning, delayed recall, savings, 
omissions and commissions in word list 
recognition, copying, visuoconstructive 
delayed recall and savings
BDI, DS forward and backward, naming, 
semantic fluency, verbal comprehension, 
omissions in visual recognition, word list 
learning, delayed recall, savings, 
omissions in word list recognition, 
visuoconstructive delayed recall and 
savings
AD BDI, word list learning, word list 
commission errors, visual recognition 
commissions
PDD
BDI = Beck Depression Inventory; DS = Digit Span; FAS = phonological word fluency test. 
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 The two groups with MCI differed in delayed recall and savings of word list learning and 
in commission errors, but not in omissions on the recognition tasks. From a cognitive point 
of view, the omissions and commissions in recognition can be linked to two distinct processes. 
According to the dual process theory of recognition  [39] , items may be remembered either by 
recollection or by familiarity. A deficit in recollection may lead to an increase of false-positive 
responses because recognition is then primarily based on the feeling of familiarity, in 
particular for related items. However, a deficit in familiarity processing might lead to less hits 
and more omissions, but not to more commission. Such dissociation was exactly what we 
found. Several previous studies  [40–44] have shown that recognition in AD patients is strongly 
influenced by item familiarity because of the fundamental deficit in episodic memory. Similar 
results for increased intrusions in AD patients, compared to patients with other kinds of 
dementia, have been shown with clinical tests  [45, 46] and with the visual recognition task 
described in the Methods section  [32] .
 Research on recognition deficits in PD patients has revealed mixed results. Recently, 
Cohn et al.  [47] have shown that memory performance of PD patients is strongly influenced 
by the nature of the encoding process: after shallow encoding, PD patients suffer from a famil-
iarity deficit and following deep encoding, they have a recollection deficit. Our two recog-
nition tasks both required visual perception (identifying objects and reading words). In the 
object recognition task, we did not inform the patients of the subsequent recognition task, 
and in the word list task, we used a set of unrelated words without any structuring cues. One 
may argue that these task characteristics do not stimulate deep encoding, and this may explain 
why PD patients suffered from a specific familiarity deficit on both recognition tasks.
 PDD patients performed better than AD patients in learning and recognition, while MCI 
PD patients scored better than aMCI patients on the recognition and delayed free recall tasks. 
First, recognition is the easiest form of consciously remembering past experiences, and 
impairment in recognition can be considered as impairment in consolidation rather than as 
impairment in delayed free recall. Second, delayed free recall relies also on executive func-
tions (strategic search processes), and this effect becomes more pronounced after a delay. 
Hence, we would argue that the difference in delayed free recall between MCI PD and aMCI 
patients disappeared in the later stage, not due to the development of a similar deficit in 
episodic memory, but due to an increasing deficit in strategic search. As this deficit is limited 
in MCI PD patients, it only affected performance in the more difficult delayed free recall task 
of word list learning and not in word list learning. Due to the higher deficit severity in PDD, it 
also affected word list learning and impaired the performance in the delayed free recall task 
to the same degree as the episodic memory deficit of the AD patients.
 This finding of a persistent difference in recognition memory between AD and PDD 
patients fits well with the progressive neuropathological characteristics of the two diseases: 
AD starts in the entorhinal cortex and the hippocampus and thus impairs recollection, where-
as in PD the main pathological feature is a decrease in the dopaminergic modulation of the 
frontal cortex  [17] . As previous studies show, in addition to other structures, the frontal 
cortex is significant for the feeling of familiarity  [48] . 
 The frontal cortex might also be involved in the increased incidence of depression as 
observed in PDD. In the beginning, the loss of dopaminergic neurons mainly occurs in the 
dorsal striatum, but in the course of the disease, it spreads to more ventral parts of the 
striatum. The ventral part of the striatum is an essential component of the basal ganglia loops, 
which instantiate cognitive and affective functions. Consequently, the decrease in familiarity 
and mood may be due to the progression of the neurodegenerative process spreading to the 
ventral striatum. A correlation between PD progression, depression and dementia has been 
shown by several studies  [3, 4, 49, 50] .
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 Certain limitations of the present study need to be acknowledged. First, we used a cross-
sectional study design, but a longitudinal design would have been more appropriate. This is 
especially true for aMCI patients since we have to assume that only a percentage of them will 
convert into AD patients. Second, the AD patients have been recruited from an inpatient 
setting, which may have introduced a selection bias. On the contrary, the diagnosis of AD has 
been based on a clinical investigation, a neuropsychological assessment and on CSF markers, 
which should have helped to avoid any major influence in the diagnosis. Third, the number of 
patients per group was low, especially in the PDD patient group.
 In summary, our results indicate that from an early state of MCI to the state of dementia 
there is a common loss of functions in AD and PD, mainly concerning parietal and temporal 
functions such as language and attention. In contrast, other cognitive and affective deficits 
remain specific for each of the two disorders, and these deficits concern recollection as medio-
temporal function and mood as basal ganglia function.
 Therefore, with respect to clinical neuropsychological assessment, our results argue for 
a differentiated evaluation of omissions and commissions in recognition tasks, apart from a 
combined evaluation of discrimination measures such as the discriminability index of the 
CERAD-NP battery. At least in this investigation, the differences between AD and PD patients 
were maximal for commission errors related to recollection and not for omission errors 
related to familiarity. For clinical purposes, this investigation also argues that it is important 
to check the diagnosis carefully in the case that probable AD patients show relevant depressive 
symptoms, since this was rarely the case in our patient groups.
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